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± 13,682 versus 567,920 ± 15,127), leading to an incremental
cost-effectiveness ratio of SEK 4373 per QALY gained for IAsp
versus HSI. From a societal perspective, IAsp was life and cost
saving (dominant) compared to HSI, assuming that workplace
productivity improved with diabetes-related complications
avoided. CONCLUSIONS: Over patient lifetimes, IAsp was pro-
jected to improve LE and QALE and reduce the cumulative inci-
dence of diabetes-related complications, with cost savings from
a societal perspective in Sweden, compared to HSI.
PDB11
LONG-TERM COST-EFFECTIVENESS ANALYSIS OF
REPAGLINIDE VERSUS NATEGLINIDE IN COMBINATION
WITH METFORMIN IN TYPE 2 DIABETES PATIENTS FAILING
MONOTHERAPY IN THE SWEDISH SETTING
Ray J1, Brandt AS2, Foos V1, Munro V3,Valentine WJ1, Roze S1,
Palmer AJ1
1CORE—Center for Outcomes Research, A Unit of IMS, Allschwil,
Basel, Switzerland, 2Novo Nordisk Scandinavia AB, Malmo, Sweden,
3Novo Nordisk Ltd, Crawley, West Sussex, UK
OBJECTIVES: To estimate the long-term clinical and economic
outcomes associated with repaglinide or nateglinide therapy,
both in combination with metformin, in patients with type 2 dia-
betes inadequately controlled with sulfonylurea or metformin
monotherapy, or with low dose glybenclamide plus metformin
in the Swedish setting. Based on the results of a recent 16-week
clinical trial. METHODS: A published and validated, interactive
computer model was adapted to project life expectancy (LE),
quality-adjusted life expectancy (QALE), cumulative incidence of
complications and costs in the Swedish setting. The model com-
prises a series of Markov sub-models that simulate the long-term
incidence and progression of diabetes-related complications
based on published data. Baseline cohort characteristics (mean
age 55.8 years, duration of diabetes 7 years, HbA1c 8.4%, BMI
33 kg.m-2) and intervention effects were derived from the clini-
cal trial. Costs were accounted from a societal perspective (treat-
ment, complication and lost-productivity costs) and expressed in
year 2005 Swedish Kronor (SEK) values. Clinical and cost out-
comes were projected over a lifetime horizon and discounted at
3% per annum. RESULTS: Repaglinide + metformin was asso-
ciated with an increase in LE of 0.21 years (9.82 ± 0.18 versus
9.61 ± 0.17) and in QALE of 0.17 quality-adjusted life years
(6.34 ± 0.12 versus 6.17 ± 0.11) compared to nateglinide + met-
formin. There was a reduced cumulative incidence of diabetes-
related complications associated with repaglinide + metformin
treatment, most notably for retinopathy and nephropathy, com-
pared to nateglinide + meformin. Lifetime costs were lower for
repaglinide + metformin compared to nateglinide + metformin
from both a third party payer (SEK 337,897 ± 11,471 versus
SEK 380,867 ± 13,226) and societal perspective (SEK 629,525
± 22,446 versus SEK 647,635 ± 21,191). CONCLUSIONS:
Treatment with repaglinide + metformin was projected to be
associated with increased time free of diabetes-related complica-
tions and dominant (cost and life saving) from a societal per-
spective, compared to nateglinide + metformin, in the Swedish
setting.
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OBJECTIVES: To project the long-term clinical and economic
outcomes associated with continuous subcutaneous insulin 
infusion (CSII) compared with multiple daily injection (MDI) 
in patients with type 1 diabetes in Sweden and Norway.
METHODS: A previously published and validated computer
simulation model of type 1 diabetes was adapted to project life
expectancy (LE), quality-adjusted life expectancy (QALE) and
costs in Norwegian and Swedish settings. Effects associated with
CSII and MDI delivery systems and baseline simulated cohort
characteristics (mean age 26 years, duration of diabetes 12 years,
54% male, mean HbA1c 8.68%) were taken from a recent meta-
analysis. Direct medical costs and indirect costs (human capital
approach) were accounted in year 2005 values. Clinical and cost
outcomes were projected over a lifetime horizon and discounted
at a rate of 3% per annum. RESULTS: CSII treatment was 
associated with increased LE versus MDI in the Norwegian 
and Swedish settings (0.95 and 1.03 years, respectively) and
increased QALE (0.98 and 1.03 quality-adjusted life years
(QALYs), respectively). The cumulative incidence of diabetes-
related complications, particularly nephropathy and retinopathy
complications was also lower in the CSII treatment arm com-
pared to MDI. Mean lifetime costs were greater for CSII treat-
ment compared to MDI in the Norwegian setting (NOK
3,505,368 ± 77,645 versus 3,480,974 ± 76,698), which pro-
duced an incremental cost-effectiveness ratio (ICER) of NOK
24,837 (∼€3200) per QALY gained for CSII versus MDI. In the
Swedish setting CSII was also associated with higher lifetime
costs compared to MDI (SEK 3,026,056 ± 58,873 vs 2,965,366
± 60,025) which led to an ICER of SEK 58,830 (∼€6300) per
QALY gained for CSII versus MDI. CONCLUSIONS: CSII was
associated with increased LE and QALE and reduced incidence
of diabetes-related complications compared to MDI. CSII repre-
sents good value for money in the Norwegian and Swedish
setting from a societal perspective by generally accepted 
standards.
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OBJECTIVES: The purpose of this study was to evaluate the rel-
ative cost effectiveness (cost utility) of insulin glargine versus
NPH insulin in the UK for the treatment of people with type 2
diabetes mellitus (T2DM) using pooled data from the Phase III
clinical trials programme. METHODS: This was a health eco-
nomic evaluation using a stochastic simulation model. Transition
probabilities for progression to diabetes-related complications
for the model were derived mainly from the UKPDS (UK
Prospective Diabetes Study) risk equations. Costs were derived
from published estimates and local data. The maximum time
horizon was 40 years to ensure effective modelling of diabetes
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patients. Utility values were extracted from the Health Outcomes
Data Repository (HODaR) and published sources. Costs were
calculated from UK £2005 prices. Costs and beneﬁts were dis-
counted annually at 3.5%. In this case, the model reported the
experiences of 1000 subjects averaged over ten repeat simula-
tions. Relative effectiveness for glycaemic control (HbA1c) and
hypoglycaemia was determined from a meta-analysis of the
pivotal clinical trials. RESULTS: Pooled analysis of pre-
registration studies showed no difference in HbA1c between
glargine-treated patients and NPH but a 40% relative risk reduc-
tion in severe hypoglycaemic episodes, a 35% relative risk reduc-
tion in nocturnal hypoglycaemic episodes and a 10% relative risk
reduction of symptomatic hypoglycaemia. Over the 40 years,
treatment with NPH resulted in 37,059 additional severe hypo-
glycaemic events, 200,416 additional nocturnal hypoglycaemic
events and 2,605,408 additional symptomatic hypoglycaemic
events compared to insulin glargine. The discounted incremen-
tal cost effectiveness ratio (ICER) was £15,197 per quality
adjusted life year (QALY) gained. Sensitivity analysis showed
these ﬁndings were robust. CONCLUSIONS: Insulin glargine is
cost effective when used as basal insulin for the treatment of
people with type 2 diabetes. The ICER is well within accepted
thresholds for cost effective treatments in the UK.
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OBJECTIVE: to evaluate the cost of the treatment of the dia-
betic patients in our means from the perspective of the NHS and
the percentage of patients treated in monotherapy and the used
combinations more. METHODS: The total of patients including
in the program of diabetes in our means was of 207. 120 clini-
cal histories by means of simple sampling studied random
coming from which they went to consultation between the 1 of
November of 2004 and the 31 of October of the 2005. The costs
of the medical consultations and inﬁrmary were obtained from
the Sanitary District of Axarquía (Málaga Est), the cost of the
used medication of the nomenclátor of the Andalusian Heatlh
Service (SAS). RESULTS: Sixty-seven percent of the patients
showed a good control of the HbA1c (according to criteria 
of ADA, 2006) with average numbers of 6.08% (IC95%:
5.95–6.21). The average total cost by patient was of €534/y
(34% by the prescription). The cost by patient according to the
degree of control of the DM was: €433 for good control (HbA1c
< 6%), €496 for a normal control (6%7%) and €685 for bad
control (HbA1c > 7%). These differences were signiﬁcant (p =
0.032). CONCLUSIONS: The percentage of control of the dia-
betics in our means is than acceptable more. Differences between
gender in the degree of control and use of resources exist,
although they were not signiﬁcant statistically. The diabetics
badly controlled cause a greater use of sanitary resources in
primary care. Most of the diabetics in our means is controlled
with monotherapy. It would be necessary to improve the
sociosanitary attention of these patients and to include the car-
diovascular risk like one more a measurement of control and
effectiveness.
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OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within an Italian setting, the cost-effectiveness
of using SMBG. METHODS: A validated, published model for
type 2 diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
from major epidemiological studies. Costs of complications were
derived from published sources. From the Italian National
Health Service perspective, direct costs of diabetes complications
and of SMBG were projected over patient lifetimes. Outcomes
were discounted at 3% annually. RESULTS: Depending on type
of treatment (diet/exercise, oral medications, or insulin), greater
glycemic control with SMBG improved (discounted) QALE by
0.05 to 0.19 QALYs and increased total costs by €1270 to €3809
per patient. The resulting incremental cost-effectiveness ratios
ranged from €20,047 to €25,400 per QALY gained, and were
well within current willingness-to-pay limits. SMBG was most
cost-effective in the sub-group of patients being treated through
diet and exercise. CONCLUSIONS: Within the three treatment
regimens examined, the addition of SMBG was associated with
increased glycemic control and with improved clinical and eco-
nomic long-term outcomes. The incremental cost-effectiveness
ratios were of magnitudes typically considered to indicate good
value for money within the Italian health service setting. Addi-
tional comparative studies are needed to further assess Utilities
and other standard outcomes associated with SMBG in patients
with type 2 diabetes.
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OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within France, the cost-effectiveness of using
SMBG. METHODS: A validated, published model for type 2
diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
